Pet TNF-α Therapeutic Antibody Development

Creative Biolabs specializes in the discovery and development of therapeutic antibodies targeting tumor necrosis factor-alpha (TNF-α) for companion animals. Chronic inflammation is a central factor in many debilitating diseases affecting dogs and cats, from autoimmune disorders to inflammatory bowel disease (IBD). Our mission is to provide innovative, safe, and effective TNF-α-targeting therapies that improve the health and quality of life of pets. By leveraging advanced R&D platforms and a deep understanding of canine and feline immunology, we support every stage of antibody development, from early discovery to preclinical evaluation.

Platforms in Therapeutic Antibody Discovery

We offer a full spectrum of platforms for the discovery and development of canine and feline therapeutic antibodies:

• Phage Display: This versatile platform enables the rapid identification of high-affinity antibodies from large combinatorial libraries, facilitating the selection of candidates with optimal binding properties.
• Single-B Cell Sorting: Allows isolation of antigen-specific B cells from immunized animals, preserving naturally paired heavy and light chains for antibody discovery.
• Hybridoma Technology: Discover monoclonal antibody and provide a reliable source of high-quality antibodies for downstream development and evaluation.

These platforms provide flexibility and precision, allowing us to develop antibodies that meet the unique immunological requirements of dogs and cats.

Comprehensive Antibody Development Services

Our comprehensive service offerings ensure seamless progression from antibody discovery to preclinical evaluation:

Antibody Characterization

Evaluate binding affinity, specificity, and functional activity to select the most promising candidates.

Antibody Engineering

Optimize antibodies for stability, reduced immunogenicity, and enhanced therapeutic efficacy.

Preclinical Evaluation

Conduct in vitro and in vivo studies in relevant species to assess safety, pharmacokinetics, and efficacy.

Antibody Development

Support scalable production, formulation, and regulatory documentation for preclinical and clinical studies.

Discover How We Can Help - Request a Consultation

Why Focus on TNF-α?

TNF-α is a pro-inflammatory cytokine that plays a critical role in mediating immune responses. While essential for host defense, excessive or dysregulated TNF-α activity contributes to chronic inflammatory diseases, autoimmune disorders, and certain cancers in pets. In dogs, elevated TNF-α levels are implicated in conditions such as inflammatory bowel disease (IBD), rheumatoid arthritis, and atopic dermatitis. In cats, TNF-α is linked to feline chronic gingivostomatitis and other inflammatory disorders. By targeting TNF-α, therapeutic antibodies can modulate pathological inflammation, reducing tissue damage and improving clinical outcomes. This makes TNF-α a highly relevant and actionable target for both canine and feline patients, addressing conditions that currently have limited treatment options.

Mechanism of Action

TNF-α-targeting antibodies function by binding to circulating TNF-α molecules, preventing their interaction with TNF receptors (TNFR1 and TNFR2) on target cells. This blockade inhibits downstream pro-inflammatory signaling pathways, including NF-κB activation, which is responsible for driving cytokine production, immune cell recruitment, and tissue damage. By neutralizing TNF-α activity, these antibodies can effectively reduce inflammation, alleviate clinical symptoms, and halt the progression of immune-mediated diseases in dogs and cats. Depending on the disease context, this mechanism can provide both systemic and localized therapeutic benefits.

Fig 1. LOAD Scores of Liverpool Osteoarthritis in Dogs.¹

Our Advantages

• Expertise in canine and feline immunology ensures antibodies are species-optimized.
• Flexible discovery platforms accelerate identification of high-affinity, functional candidates.
• Comprehensive services reduce development timelines by integrating discovery, engineering, and preclinical evaluation.
• Tailored solutions address both common and rare TNF-α-mediated conditions in companion animals.
• Access to preclinical models and evaluation services ensures data-driven decision-making and regulatory readiness.

Partner with Creative Biolabs

Creative Biolabs is committed to advancing veterinary medicine through innovative therapeutic antibodies. Whether your goal is to develop first-in-class TNF-α-targeting antibodies or enhance existing therapies, we provide the expertise, platforms, and end-to-end support to bring your project from concept to preclinical proof-of-concept. Partner with Creative Biolabs to deliver cutting-edge therapies that transform the treatment of inflammatory diseases in companion animals.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Nakanishi, Aoi et al. "A Pilot, Open-Label Study to Evaluate the Efficacy of Intra-Articular Administration of a Caninized TNF Receptor Fc Fusion Protein as a Treatment for Osteoarthritis-Associated Joint Pain." Frontiers in veterinary science vol. 9 836709. 2 Jun. 2022. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fvets.2022.836709